Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy

Gelijkaardige items

• The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial
  door: Lærke K. Tolstrup, et al.
  Gepubliceerd in: (2020-10-01)
• A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
  door: Mille Guldager Christiansen, et al.
  Gepubliceerd in: (2023-07-01)
• Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial
  door: Lærke K. Tolstrup, et al.
  Gepubliceerd in: (2022-01-01)
• Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
  door: Minji K. Lee, et al.
  Gepubliceerd in: (2020-12-01)
• Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)
  door: Evalien Veldhuijzen, et al.
  Gepubliceerd in: (2020-10-01)